Biological products, except diagnostic Stocks List

This page shows information about the 50 largest biological products, except diagnostic industry stocks including Amgen, Gilead Sciences, argenx, and BioNTech.

1. Amgen NASDAQ:AMGN

$311.68 -7.21 (-2.26%)

As of 03:53 PM Eastern

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. More about Amgen

Pros of Amgen

Amgen Inc. has a strong dividend yield of 3.01%, providing a steady income stream for investors. The recent quarterly dividend of $2.38 per share reflects the company's commitment to returning value to shareholders.
The company reported a robust earnings per share (EPS) of $5.31, exceeding analysts' expectations, which indicates strong financial performance and potential for future growth.
Amgen Inc. has a diverse portfolio of innovative therapeutics, including recent advancements in treatments for conditions like osteoporosis and chronic gout, which positions the company well in the healthcare market.

Cons of Amgen

Amgen Inc. has a high dividend payout ratio of 126.09%, which may raise concerns about the sustainability of its dividend payments in the long term, especially if earnings do not continue to grow.
The company's stock price has fluctuated, with a 52-week range between $253.30 and $346.85, indicating potential volatility that could affect investor returns.
Amgen Inc. has a high debt-to-equity ratio of 9.62, suggesting that the company relies heavily on debt financing, which could pose risks if market conditions change.

A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.

Market Capitalization: $167.56 billion
P/E Ratio: 41.31
Consensus Rating: Hold
Consensus Price Target: $314.04 (+0.8% Upside)
Volume: 2.24 million shares
Average Volume: 2.55 million shares
Today's Range: $308.64
▼
$316.02
50-Day Range: $258.59
▼
$327.36
52-Week Range: $253.30
▼
$346.85
Dividend Yield: 3.00%

2. Gilead Sciences NASDAQ:GILD

$113.88 -0.55 (-0.48%)

As of 03:53 PM Eastern

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. More about Gilead Sciences

Pros of Gilead Sciences

Gilead Sciences, Inc. recently reported earnings per share (EPS) of $1.90, surpassing analysts' expectations of $1.67, indicating strong financial performance and potential for growth.
The company has increased its quarterly dividend to $0.79 per share, up from $0.77, reflecting a commitment to returning value to shareholders. This translates to an annualized dividend of $3.16, providing a yield of 2.76%.
With a return on equity of 31.63%, Gilead Sciences, Inc. demonstrates effective management and profitability, which can be attractive to investors looking for solid returns on their investments.

Cons of Gilead Sciences

The company's high dividend payout ratio of 854.05% raises concerns about sustainability, as it indicates that Gilead Sciences, Inc. is paying out significantly more in dividends than it earns in net income.
Insider selling activity, with executives selling over 293,000 shares recently, may signal a lack of confidence in the company's future performance, which could deter potential investors.
Despite positive earnings, the net margin of 1.67% suggests that the company may face challenges in maintaining profitability, which could impact future growth and investor returns.

A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.

Market Capitalization: $141.94 billion
P/E Ratio: 308.04
Consensus Rating: Moderate Buy
Consensus Price Target: $104.52 (-8.2% Downside)
Volume: 5.60 million shares
Average Volume: 8.19 million shares
Today's Range: $112.82
▼
$114.87
50-Day Range: $89.14
▼
$117.41
52-Week Range: $62.07
▼
$119.96
Dividend Yield: 2.65%

3. argenx NASDAQ:ARGX

$591.38 +10.95 (+1.89%)

As of 03:53 PM Eastern

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. More about argenx

Pros of argenx

argenx SE's lead product candidate, efgartigimod, is showing promise in treating multiple autoimmune diseases, which could lead to significant revenue growth as these therapies gain approval and market traction.
The company has a strong institutional backing, with 60.32% of its stock owned by institutional investors and hedge funds, indicating confidence in its long-term prospects.
As of the latest trading session, argenx SE's stock price is $626.13, reflecting a robust market capitalization of $38.04 billion, which suggests a solid position in the biotechnology sector.

Cons of argenx

The stock has a high P/E ratio of -711.51, which indicates that the company is not currently profitable, raising concerns about its financial sustainability.
Recent trading activity shows volatility, with shares trading down 2.8% in a single session, which may indicate market uncertainty regarding the company's future performance.
Despite positive analyst ratings, one research analyst has issued a sell rating, suggesting that there are differing opinions on the stock's future performance.

A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.

Market Capitalization: $35.80 billion
P/E Ratio: -669.52
Consensus Rating: Moderate Buy
Consensus Price Target: $687.00 (+16.2% Upside)
Volume: 183,457 shares
Average Volume: 283,635 shares
Today's Range: $583.45
▼
$593.10
50-Day Range: $571.00
▼
$671.74
52-Week Range: $349.86
▼
$678.21
Dividend Yield: N/A

4. BioNTech NASDAQ:BNTX

$100.16 +1.77 (+1.79%)

As of 03:53 PM Eastern

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. More about BioNTech

Pros of BioNTech

BioNTech SE has a strong market capitalization of $28.26 billion, indicating a robust financial position and potential for growth.
The company has received multiple "buy" ratings from analysts, with a consensus target price of $142.72, suggesting that there is optimism about its future performance.
Recent earnings reports show that BioNTech SE beat analysts' expectations with an earnings per share (EPS) of $1.08, which is a positive indicator of profitability.

Cons of BioNTech

The company has a negative price-to-earnings ratio of -56.13, indicating that it is currently not profitable, which can be a red flag for potential investors.
BioNTech SE reported a year-over-year revenue decline of 19.5%, which may suggest challenges in maintaining sales and market share.
The firm has a negative return on equity of 2.35%, indicating that it is not generating profit from its equity, which could deter investors looking for strong financial performance.

A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.

Market Capitalization: $23.97 billion
P/E Ratio: -47.60
Consensus Rating: Moderate Buy
Consensus Price Target: $143.65 (+43.4% Upside)
Volume: 907,202 shares
Average Volume: 795,861 shares
Today's Range: $97.82
▼
$101.08
50-Day Range: $98.39
▼
$126.88
52-Week Range: $76.53
▼
$131.49
Dividend Yield: N/A

5. Biogen NASDAQ:BIIB

$140.08 -3.58 (-2.49%)

As of 03:53 PM Eastern

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. More about Biogen

Pros of Biogen

Biogen Inc. has a strong market presence with a market capitalization of approximately $22.01 billion, indicating its stability and potential for growth in the biotechnology sector.
The company recently reported earnings per share (EPS) of $3.44, surpassing analysts' expectations, which reflects its strong financial performance and ability to generate profit.
With a current stock price of $150.38, Biogen Inc. is positioned at a reasonable valuation compared to its 12-month high of $238.00, suggesting potential for price appreciation.

Cons of Biogen

Despite recent positive earnings, the stock has experienced volatility, with a 12-month low of $128.51, which may raise concerns about its stability.
The company has a relatively low quick ratio of 0.90, suggesting potential liquidity issues that could affect its ability to meet short-term obligations.
Biogen Inc. has a price-to-earnings (P/E) ratio of 13.44, which, while not excessively high, may indicate that the stock is not undervalued compared to its earnings potential.

A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.

Market Capitalization: $20.53 billion
P/E Ratio: 12.54
Consensus Rating: Hold
Consensus Price Target: $213.33 (+52.3% Upside)
Volume: 1.41 million shares
Average Volume: 1.55 million shares
Today's Range: $140.32
▼
$143.13
50-Day Range: $133.43
▼
$153.27
52-Week Range: $128.51
▼
$238.00
Dividend Yield: N/A

Remove Ads

6. Moderna NASDAQ:MRNA

$34.95 +1.19 (+3.52%)

As of 03:53 PM Eastern

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. More about Moderna

Pros of Moderna

Moderna, Inc. has a significant market capitalization of $13.05 billion, indicating a strong presence in the biotechnology sector, which can attract institutional investors and provide stability.
Recent institutional inflows show a positive trend, with several hedge funds increasing their stakes in the company, suggesting growing confidence in its future performance.
The current stock price is $33.22, which may present a buying opportunity for investors looking for potential growth, especially considering the company's innovative mRNA technology.

Cons of Moderna

Insider selling has been observed, with 2,664 shares sold recently, which could signal a lack of confidence among executives regarding the company's short-term prospects.
The company has a negative P/E ratio of -3.65, indicating that it is currently not profitable, which can be a red flag for potential investors.
Moderna, Inc. has experienced significant volatility, with a 1-year high of $170.47 and a low of $29.25, suggesting that the stock may be subject to large price swings, which can be risky for investors.

A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.

Market Capitalization: $13.48 billion
P/E Ratio: -3.77
Consensus Rating: Hold
Consensus Price Target: $60.63 (+73.5% Upside)
Volume: 5.07 million shares
Average Volume: 12.52 million shares
Today's Range: $33.79
▼
$35.29
50-Day Range: $30.27
▼
$47.53
52-Week Range: $29.25
▼
$170.47
Dividend Yield: N/A

7. Neurocrine Biosciences NASDAQ:NBIX

$108.63 +1.41 (+1.32%)

As of 03:53 PM Eastern

Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids. Its product candidates in clinical development include valbenazine to treat dyskinetic cerebral palsy in pediatrics and adults; NBI-921352 to treat developmental and epileptic encephalopathy syndrome in pediatrics and adults; NBI-827104 to treat epileptic encephalopathy with continuous spike-and-wave during sleep; NBI-1076986 to treat movement disorders; crinecerfront to treat congenital adrenal hyperplasia in adults and children; EFMODY to treat congenital adrenal hyperplasia and adrenal insufficiency in adults; valbenazine for the adjunctive treatment of schizophrenia; NBI-1065845 for the treatment of inadequate response to treatment in major depressive disorder; luvadaxistat to treat cognitive impairment related to schizophrenia; NBI-1117568 for the treatment of schizophrenia; NBI-1070770 to treat major depressive disorder; NBI-1117570 for the treatment of symptoms of psychosis and cognition in neurological and neuropsychiatric conditions; and NBI-1117569, NBI-1117567, and NBI-1065890 to treat CNS indications. The company also has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.

Market Capitalization: $10.83 billion
P/E Ratio: 33.00
Consensus Rating: Moderate Buy
Consensus Price Target: $165.24 (+52.1% Upside)
Volume: 875,533 shares
Average Volume: 1.35 million shares
Today's Range: $106.83
▼
$109.56
50-Day Range: $107.22
▼
$153.29
52-Week Range: $105.18
▼
$157.98
Dividend Yield: N/A

8. Exelixis NASDAQ:EXEL

$37.16 +0.24 (+0.64%)

As of 03:53 PM Eastern

Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat specific forms of advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. It develops zanzalintinib, a novel, potent, next-generation oral tyrosine kinase inhibitor (TKI) that targets VEGF receptors, MET and the TAM kinases (TYRO3, AXL and MER); and XB002, a next-generation tissue factor (TF)-targeting ADC, administered via intravenous infusion and composed of a human monoclonal antibody (mAb) against TF that is conjugated to an auristatin-based microtubulin inhibitor (MTI) payload. It has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited, as well as clinical development agreement with Sairopa B.V. for ADU-1805. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.

Market Capitalization: $10.38 billion
P/E Ratio: 20.95
Consensus Rating: Moderate Buy
Consensus Price Target: $37.24 (+0.2% Upside)
Volume: 1.70 million shares
Average Volume: 2.08 million shares
Today's Range: $36.68
▼
$37.32
50-Day Range: $32.38
▼
$39.15
52-Week Range: $20.14
▼
$40.02
Dividend Yield: N/A

9. Vaxcyte NASDAQ:PCVX

$73.69 +3.84 (+5.50%)

As of 03:53 PM Eastern

Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.

Market Capitalization: $9.53 billion
P/E Ratio: -16.10
Consensus Rating: Buy
Consensus Price Target: $147.50 (+100.2% Upside)
Volume: 903,120 shares
Average Volume: 1.18 million shares
Today's Range: $70.00
▼
$75.00
50-Day Range: $68.89
▼
$92.13
52-Week Range: $58.10
▼
$121.06
Dividend Yield: N/A

10. Bio-Techne NASDAQ:TECH

$60.10 +1.63 (+2.79%)

As of 03:53 PM Eastern

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets in the United States, the United Kingdom, rest of Europe, Middle East, and Africa, Greater China, rest of Asia-Pacific, and internationally. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.

Market Capitalization: $9.47 billion
P/E Ratio: 60.53
Consensus Rating: Moderate Buy
Consensus Price Target: $82.14 (+36.7% Upside)
Volume: 2.67 million shares
Average Volume: 1.06 million shares
Today's Range: $56.60
▼
$60.30
50-Day Range: $58.47
▼
$78.75
52-Week Range: $56.66
▼
$85.57
Dividend Yield: 0.50%

Remove Ads

11. Qiagen NYSE:QGEN

$39.44 +0.19 (+0.48%)

As of 03:53 PM Eastern

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials. The firm assay technologies make these biomolecules visible and ready for analysis. Its bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. The company was founded by Detlev H. Riesner and Metin Colpan on April 29, 1996, and is headquartered in Venlo, the Netherlands.

Market Capitalization: $8.76 billion
P/E Ratio: 109.94
Consensus Rating: Hold
Consensus Price Target: $47.71 (+21.0% Upside)
Volume: 862,538 shares
Average Volume: 1.26 million shares
Today's Range: $38.94
▼
$39.60
50-Day Range: $37.85
▼
$46.22
52-Week Range: $37.63
▼
$49.30
Dividend Yield: N/A

12. Repligen NASDAQ:RGEN

$145.96 -1.17 (-0.79%)

As of 03:53 PM Eastern

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands. The company was incorporated in 1981 and is headquartered in Waltham, Massachusetts.

Market Capitalization: $8.22 billion
P/E Ratio: -287.71
Consensus Rating: Moderate Buy
Consensus Price Target: $181.00 (+24.0% Upside)
Volume: 443,194 shares
Average Volume: 641,665 shares
Today's Range: $141.26
▼
$149.66
50-Day Range: $136.99
▼
$174.24
52-Week Range: $113.50
▼
$200.23
Dividend Yield: N/A

13. Halozyme Therapeutics NASDAQ:HALO

$60.81 -0.64 (-1.04%)

As of 03:53 PM Eastern

Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; rilpivirine, cabotegravir, and N6LS BNAB for the treatment of HIV; ocrelizumab for multiple sclerosis; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of chronic lymphocytic leukemia; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergic reactions; nivolumab+relatlimab and ANTI-TIM3 for the treatment of solid tumors; ARGX-117 for multifocal motor neuropathy; atezolizumab; nivolumab; afgartigimod; teriparatide injections; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.

Market Capitalization: $7.45 billion
P/E Ratio: 17.64
Consensus Rating: Moderate Buy
Consensus Price Target: $62.78 (+3.2% Upside)
Volume: 711,886 shares
Average Volume: 1.31 million shares
Today's Range: $60.50
▼
$62.03
50-Day Range: $47.74
▼
$61.45
52-Week Range: $37.73
▼
$65.53
Dividend Yield: N/A

14. Revolution Medicines NASDAQ:RVMD

$39.04 +0.15 (+0.39%)

As of 03:53 PM Eastern

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

Market Capitalization: $7.26 billion
P/E Ratio: -10.88
Consensus Rating: Buy
Consensus Price Target: $66.31 (+69.8% Upside)
Volume: 860,529 shares
Average Volume: 1.36 million shares
Today's Range: $38.57
▼
$40.87
50-Day Range: $36.82
▼
$44.42
52-Week Range: $29.55
▼
$62.40
Dividend Yield: N/A

15. Krystal Biotech NASDAQ:KRYS

$179.04 -5.84 (-3.16%)

As of 03:53 PM Eastern

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.

Market Capitalization: $5.15 billion
P/E Ratio: 59.80
Consensus Rating: Buy
Consensus Price Target: $220.00 (+22.9% Upside)
Volume: 144,602 shares
Average Volume: 290,848 shares
Today's Range: $178.90
▼
$184.64
50-Day Range: $142.64
▼
$187.86
52-Week Range: $141.72
▼
$219.34
Dividend Yield: N/A

Remove Ads

16. ADMA Biologics NASDAQ:ADMA

$18.44 +1.10 (+6.31%)

As of 03:53 PM Eastern

ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.

Market Capitalization: $4.34 billion
P/E Ratio: 65.53
Consensus Rating: Buy
Consensus Price Target: $22.50 (+22.0% Upside)
Volume: 2.72 million shares
Average Volume: 3.32 million shares
Today's Range: $17.80
▼
$18.56
50-Day Range: $15.44
▼
$19.13
52-Week Range: $5.88
▼
$23.64
Dividend Yield: N/A

17. Arcellx NASDAQ:ACLX

$72.50 +4.14 (+6.06%)

As of 03:53 PM Eastern

Arcellx, Inc., together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company's lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM). It also develops ACLX-001, a product candidate in Phase 1 clinical trials targeting BCMA to treat rrMM; and ACLX-002, which is in Phase 1 clinical trials that targets CD123 for treating relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). In addition, the company's preclinical product includes ACLX-003 for the treatment of AML and MDS. Further, it focuses on the development of product candidates for solid tumor programs. It has a strategic alliance with Kite Pharma, Inc. to co-develop and co-commercialize anitocabtagene autoleucel. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

Market Capitalization: $3.98 billion
P/E Ratio: -102.07
Consensus Rating: Buy
Consensus Price Target: $108.46 (+49.6% Upside)
Volume: 522,341 shares
Average Volume: 657,475 shares
Today's Range: $68.04
▼
$73.06
50-Day Range: $60.26
▼
$79.13
52-Week Range: $47.88
▼
$107.37
Dividend Yield: N/A

18. SpringWorks Therapeutics NASDAQ:SWTX

$50.78 -0.12 (-0.23%)

As of 03:53 PM Eastern

SpringWorks Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer. The company is also involved in the development of mirdametinib, an oral small molecule MEK inhibitor that is in Phase 2b clinical trials for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN); mirdametinib + lifirafenib, a combination therapy that is in Phase 1b clinical trial in patients with advanced or refractory solid tumors; and mirdametinib in monotherapy and combination approaches to treat other genetically defined solid tumors, including Phase 1/2 clinical trial for the treatment of pediatric and young adult patients with low-grade gliomas. In addition, it develops Brimarafenib (BGB-3245), an oral selective small molecule inhibitor of monomeric and dimeric forms of activating BRAF mutations. The company has collaborations with BeiGene, Ltd. and GlaxoSmithKline LLC; and license agreements with Pfizer Inc. for nirogacestat and mirdametinib. It also has a license agreement with Katholieke Universiteit Leuven and the Flanders Institute for Biotechnology for a portfolio of novel small molecule inhibitors of the TEA Domain; and Dana-Farber Cancer Institute for a portfolio of novel small molecule inhibitors of Epidermal Growth Factor Receptor. The company was founded in 2017 and is headquartered in Stamford, Connecticut.

Market Capitalization: $3.79 billion
P/E Ratio: -14.53
Consensus Rating: Buy
Consensus Price Target: $73.20 (+44.2% Upside)
Volume: 1.33 million shares
Average Volume: 1.25 million shares
Today's Range: $50.31
▼
$52.40
50-Day Range: $32.50
▼
$59.93
52-Week Range: $28.21
▼
$62.00
Dividend Yield: N/A

19. CRISPR Therapeutics NASDAQ:CRSP

$43.51 +1.14 (+2.68%)

As of 03:53 PM Eastern

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.

Market Capitalization: $3.73 billion
P/E Ratio: -9.95
Consensus Rating: Hold
Consensus Price Target: $73.11 (+68.0% Upside)
Volume: 971,857 shares
Average Volume: 2.25 million shares
Today's Range: $42.42
▼
$43.94
50-Day Range: $38.36
▼
$53.02
52-Week Range: $36.52
▼
$76.86
Dividend Yield: N/A

20. Alvotech NASDAQ:ALVO

$11.36 +0.56 (+5.13%)

As of 03:53 PM Eastern

Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as age-related macular degeneration, macular edema, and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia, which is in the pre-clinical phase to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass. In addition, it offers AVT05, a biosimilar to Simponi and Simponi Aria, which is in early phase development to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other indications; AVT16, a biosimilar to an Entyvio product; AVT23, a biosimilar to Xolair, which is in late-stage development to treat nasal polyps; and AVT33, a biosimilar to an Keytruda product. Alvotech was founded in 2013 and is based in Luxembourg, Luxembourg.

Market Capitalization: $3.42 billion
P/E Ratio: -6.14
Consensus Rating: Buy
Consensus Price Target: $18.00 (+58.4% Upside)
Volume: 72,532 shares
Average Volume: 138,283 shares
Today's Range: $10.90
▼
$11.73
50-Day Range: $10.70
▼
$13.52
52-Week Range: $9.15
▼
$15.83
Dividend Yield: N/A

Remove Ads

21. Scholar Rock NASDAQ:SRRK

$35.80 +1.30 (+3.78%)

As of 03:53 PM Eastern

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is developing a pipeline of product candidates to deliver novel therapies to treat a range of serious diseases, including neuromuscular disorders, cardiometabolic disorders, cancer, fibrosis, and iron-restricted anemia. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.

Market Capitalization: $3.37 billion
P/E Ratio: -15.15
Consensus Rating: Buy
Consensus Price Target: $40.43 (+12.9% Upside)
Volume: 541,526 shares
Average Volume: 1.16 million shares
Today's Range: $35.34
▼
$37.30
50-Day Range: $34.50
▼
$46.73
52-Week Range: $6.76
▼
$46.98
Dividend Yield: N/A

22. Immunovant NASDAQ:IMVT

$19.11 -0.50 (-2.55%)

As of 03:53 PM Eastern

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.

Market Capitalization: $3.24 billion
P/E Ratio: -7.28
Consensus Rating: Buy
Consensus Price Target: $43.55 (+127.9% Upside)
Volume: 823,845 shares
Average Volume: 1.23 million shares
Today's Range: $18.94
▼
$19.83
50-Day Range: $18.44
▼
$25.19
52-Week Range: $17.65
▼
$35.97
Dividend Yield: N/A

23. Recursion Pharmaceuticals NASDAQ:RXRX

$6.20 +0.15 (+2.39%)

As of 03:53 PM Eastern

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.

Market Capitalization: $2.49 billion
P/E Ratio: -4.06
Consensus Rating: Hold
Consensus Price Target: $8.25 (+33.0% Upside)
Volume: 15.09 million shares
Average Volume: 25.40 million shares
Today's Range: $5.93
▼
$6.31
50-Day Range: $6.06
▼
$10.87
52-Week Range: $5.60
▼
$12.36
Dividend Yield: N/A

24. ImmunityBio NASDAQ:IBRX

$2.88 +0.06 (+1.95%)

As of 03:53 PM Eastern

ImmunityBio, Inc., a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies. The company's platforms have generated therapeutic agents that are currently being or planned to be studied in clinical trials across various indications in liquid and solid tumors, including bladder, lung and colorectal cancers, and glioblastoma multiforme. Its lead biologic product candidate is Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. The company has collaboration agreements with National Cancer Institute. It also has license agreements with 3M Innovative Properties Company; Access to Advanced Health Institute; LadRx Corporation; Sanford Health; Shenzhen Beike Biotechnology Co. Ltd.; Viracta Therapeutics, Inc.; and GlobeImmune, Inc. The company is based in San Diego, California.

Market Capitalization: $2.44 billion
P/E Ratio: -3.10
Consensus Rating: Buy
Consensus Price Target: $12.19 (+323.9% Upside)
Volume: 2.83 million shares
Average Volume: 6.20 million shares
Today's Range: $2.80
▼
$2.98
50-Day Range: $2.32
▼
$3.90
52-Week Range: $2.28
▼
$10.53
Dividend Yield: N/A

25. Twist Bioscience NASDAQ:TWST

$39.38 +0.25 (+0.64%)

As of 03:53 PM Eastern

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It also provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels, primarily used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, the company provides synthetic SARS-CoV-2 RNA reference sequences as positive controls for the development of both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries used for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company was incorporated in 2013 and is headquartered in South San Francisco, California.

Market Capitalization: $2.34 billion
P/E Ratio: -11.59
Consensus Rating: Moderate Buy
Consensus Price Target: $54.40 (+38.1% Upside)
Volume: 747,347 shares
Average Volume: 996,657 shares
Today's Range: $38.47
▼
$41.45
50-Day Range: $36.71
▼
$54.07
52-Week Range: $27.41
▼
$60.90
Dividend Yield: N/A

Remove Ads

26. Denali Therapeutics NASDAQ:DNLI

$16.02 +0.98 (+6.51%)

As of 03:53 PM Eastern

Denali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; DNL343 eIF2B Activator program for amyotrophic lateral sclerosis; and SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases. It also provides early stage program include TAK-594/DNL593 program for FTD-GRN; DNL126 program for MPS IIIA, a Sanfilippo Syndrome A; DNL622 for MPS I which is Hurler syndrome; Antibody Transport Vehicle Amyloid beta program; Oligonucleotide Transport Vehicle platform, a novel class of biotherapeutics to address the root cause of diseases through modulation of gene expression; and other TV-enabled discovery programs. The company has collaboration agreements with Biogen MA Inc. and Biogen International GmbH; Genzyme Corporation; Takeda Pharmaceutical Company Limited; F-star Gamma Limited, F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H, and F-star Biotechnology Limited; and Genentech, Inc. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.

Market Capitalization: $2.32 billion
P/E Ratio: -5.78
Consensus Rating: Moderate Buy
Consensus Price Target: $37.20 (+132.2% Upside)
Volume: 1.17 million shares
Average Volume: 1.01 million shares
Today's Range: $15.10
▼
$16.28
50-Day Range: $14.95
▼
$23.59
52-Week Range: $14.01
▼
$33.33
Dividend Yield: N/A

27. Vericel NASDAQ:VCEL

$45.61 -2.20 (-4.60%)

As of 03:53 PM Eastern

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.

Market Capitalization: $2.28 billion
P/E Ratio: 759.38
Consensus Rating: Buy
Consensus Price Target: $62.29 (+36.6% Upside)
Volume: 373,109 shares
Average Volume: 419,025 shares
Today's Range: $45.55
▼
$48.51
50-Day Range: $47.81
▼
$61.80
52-Week Range: $39.12
▼
$63.00
Dividend Yield: N/A

28. Beam Therapeutics NASDAQ:BEAM

$27.34 +0.92 (+3.48%)

As of 03:53 PM Eastern

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.

Market Capitalization: $2.27 billion
P/E Ratio: -15.40
Consensus Rating: Buy
Consensus Price Target: $50.82 (+85.9% Upside)
Volume: 1.81 million shares
Average Volume: 1.20 million shares
Today's Range: $26.77
▼
$28.49
50-Day Range: $23.30
▼
$34.16
52-Week Range: $20.84
▼
$37.49
Dividend Yield: N/A

29. Kymera Therapeutics NASDAQ:KYMR

$34.88 +1.61 (+4.85%)

As of 03:53 PM Eastern

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

Market Capitalization: $2.26 billion
P/E Ratio: -14.89
Consensus Rating: Moderate Buy
Consensus Price Target: $56.69 (+62.5% Upside)
Volume: 346,710 shares
Average Volume: 586,303 shares
Today's Range: $33.24
▼
$35.18
50-Day Range: $29.98
▼
$44.36
52-Week Range: $29.07
▼
$53.27
Dividend Yield: N/A

30. CG Oncology NASDAQ:CGON

$26.64 +0.34 (+1.31%)

As of 03:53 PM Eastern

CG Oncology, Inc., an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients. It also develops PIVOT-006, a cretostimogene monotherapy for intermediate-risk NMIBC following transurethral resection of the bladder tumor; and CORE-008 for treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC patients. CG Oncology, Inc. was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. The company was founded in 2010 and is based in Irvine, California.

Market Capitalization: $2.02 billion
P/E Ratio: N/A
Consensus Rating: Buy
Consensus Price Target: $63.88 (+139.7% Upside)
Volume: 466,068 shares
Average Volume: 582,524 shares
Today's Range: $26.32
▼
$27.05
50-Day Range: $24.64
▼
$31.01
52-Week Range: $23.91
▼
$46.99
Dividend Yield: N/A

Remove Ads

31. Tarsus Pharmaceuticals NASDAQ:TARS

$47.22 +0.07 (+0.14%)

As of 03:53 PM Eastern

Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. It is developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other infectious disease prevention. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.

Market Capitalization: $1.82 billion
P/E Ratio: -12.44
Consensus Rating: Buy
Consensus Price Target: $63.67 (+34.8% Upside)
Volume: 332,630 shares
Average Volume: 637,405 shares
Today's Range: $46.92
▼
$49.90
50-Day Range: $41.29
▼
$56.94
52-Week Range: $20.08
▼
$57.28
Dividend Yield: N/A

32. Apogee Therapeutics NASDAQ:APGE

$39.29 -0.98 (-2.43%)

As of 03:53 PM Eastern

Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs comprise APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. Apogee Therapeutics, Inc. was incorporated in 2022 and is headquartered in Waltham, Massachusetts.

Market Capitalization: $1.77 billion
P/E Ratio: -16.23
Consensus Rating: Buy
Consensus Price Target: $91.60 (+133.1% Upside)
Volume: 614,894 shares
Average Volume: 493,319 shares
Today's Range: $39.06
▼
$41.87
50-Day Range: $30.37
▼
$49.57
52-Week Range: $29.10
▼
$72.29
Dividend Yield: N/A

33. Mesoblast NASDAQ:MESO

$13.43 +0.15 (+1.13%)

As of 03:53 PM Eastern

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, acute respiratory distress syndrome, and biologic refractory inflammatory bowel disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy; and MPC-25-IC for the treatment or prevention of acute myocardial infarction. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. The company was incorporated in 2004 and is headquartered in Melbourne, Australia.

Market Capitalization: $1.71 billion
P/E Ratio: N/A
Consensus Rating: Buy
Consensus Price Target: $18.00 (+34.0% Upside)
Volume: 359,816 shares
Average Volume: 737,035 shares
Today's Range: $13.39
▼
$13.95
50-Day Range: $13.07
▼
$20.61
52-Week Range: $2.05
▼
$22.00
Dividend Yield: N/A

34. BioCryst Pharmaceuticals NASDAQ:BCRX

$7.70 +0.16 (+2.06%)

As of 03:53 PM Eastern

BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.

Market Capitalization: $1.61 billion
P/E Ratio: -12.63
Consensus Rating: Moderate Buy
Consensus Price Target: $15.57 (+102.4% Upside)
Volume: 2.93 million shares
Average Volume: 2.79 million shares
Today's Range: $7.59
▼
$7.95
50-Day Range: $7.06
▼
$9.39
52-Week Range: $4.03
▼
$9.50
Dividend Yield: N/A

35. Immunocore NASDAQ:IMCR

$29.12 +0.71 (+2.48%)

As of 03:53 PM Eastern

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma. In addition, the company's product pipeline comprises IMC-F106C, which is in a Phase 3 clinical trial to treat first line advanced cutaneous melanoma; and in a Phase 1/2 clinical trial in multiple tumor types, such as platinum resistant ovarian, non-small cell lung, and endometrial carcinoma. Further, it develops IMC-R117C, which is in phase 1 clinical trial to treat colorectal and gastrointestinal cancers; IMC-M113V, which is in phase 1 clinical trial to treat human immunosuppression virus; IMC-I109V, which is in a Phase I clinical trial in patients with chronic hepatitis B virus; IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-P115C, which is in preclinical trial to treat multiple solid tumor cancers; and IMC-S118AI to treat type 1 diabetes and is in preclinical trial. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.

Market Capitalization: $1.45 billion
P/E Ratio: -30.49
Consensus Rating: Moderate Buy
Consensus Price Target: $65.64 (+125.4% Upside)
Volume: 272,510 shares
Average Volume: 432,572 shares
Today's Range: $28.11
▼
$29.33
50-Day Range: $28.20
▼
$33.00
52-Week Range: $27.19
▼
$66.00
Dividend Yield: N/A

Remove Ads

36. Novavax NASDAQ:NVAX

$8.09 +0.17 (+2.08%)

As of 03:53 PM Eastern

Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.

Market Capitalization: $1.30 billion
P/E Ratio: -3.58
Consensus Rating: Hold
Consensus Price Target: $18.00 (+122.6% Upside)
Volume: 2.08 million shares
Average Volume: 8.03 million shares
Today's Range: $7.86
▼
$8.19
50-Day Range: $7.06
▼
$10.82
52-Week Range: $3.81
▼
$23.86
Dividend Yield: N/A

37. Iovance Biotherapeutics NASDAQ:IOVA

$3.80 -0.10 (-2.44%)

As of 03:53 PM Eastern

Iovance Biotherapeutics, Inc., a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma. It also develops lifileucel in combination with pembrolizumab to treat frontline advanced melanoma patients; LN-145 for the treatment of non-small cell lung cancer (NSCLC) and solid tumor cancers; IOV-4001, which is in Phase 1/2 IOV-GM1-201 clinical trial, for the treatment of NSCLC; and lifileucel for gynecological cancers. The company has collaborations and licensing agreements with WuXi Advanced Therapies, Inc.; National Institutes of Health; the National Cancer Institute; H. Lee Moffitt Cancer Center; The University of Texas M.D. Anderson Cancer Center; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.

Market Capitalization: $1.25 billion
P/E Ratio: -2.55
Consensus Rating: Moderate Buy
Consensus Price Target: $20.25 (+432.2% Upside)
Volume: 6.07 million shares
Average Volume: 6.95 million shares
Today's Range: $3.73
▼
$4.01
50-Day Range: $3.73
▼
$7.79
52-Week Range: $3.58
▼
$15.90
Dividend Yield: N/A

38. Adaptive Biotechnologies NASDAQ:ADPT

$7.69 +0.20 (+2.72%)

As of 03:53 PM Eastern

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.

Market Capitalization: $1.15 billion
P/E Ratio: -7.09
Consensus Rating: Moderate Buy
Consensus Price Target: $9.10 (+18.3% Upside)
Volume: 1.68 million shares
Average Volume: 1.71 million shares
Today's Range: $7.43
▼
$7.89
50-Day Range: $5.99
▼
$8.52
52-Week Range: $2.28
▼
$8.95
Dividend Yield: N/A

39. Vir Biotechnology NASDAQ:VIR

$7.37 +0.03 (+0.37%)

As of 03:53 PM Eastern

Vir Biotechnology, Inc., an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; collaboration with WuXi Biologics (Hong Kong) Limited and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. The company was incorporated in 2016 and is headquartered in San Francisco, California.

Market Capitalization: $1.00 billion
P/E Ratio: -1.87
Consensus Rating: Moderate Buy
Consensus Price Target: $35.67 (+384.1% Upside)
Volume: 558,589 shares
Average Volume: 2.28 million shares
Today's Range: $7.23
▼
$7.46
50-Day Range: $7.27
▼
$12.48
52-Week Range: $6.56
▼
$14.45
Dividend Yield: N/A

40. Replimune Group NASDAQ:REPL

$12.11 +0.67 (+5.85%)

As of 03:53 PM Eastern

Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma. The company is also developing RP2, which is in Phase I clinical trials to express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trial to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.

Market Capitalization: $932.65 million
P/E Ratio: -3.94
Consensus Rating: Buy
Consensus Price Target: $19.43 (+60.4% Upside)
Volume: 472,011 shares
Average Volume: 865,945 shares
Today's Range: $11.47
▼
$12.38
50-Day Range: $10.14
▼
$14.31
52-Week Range: $4.92
▼
$17.00
Dividend Yield: N/A

Remove Ads

41. Anavex Life Sciences NASDAQ:AVXL

$8.92 -0.06 (-0.71%)

As of 03:53 PM Eastern

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.

Market Capitalization: $757.16 million
P/E Ratio: -16.18
Consensus Rating: Buy
Consensus Price Target: $44.00 (+393.5% Upside)
Volume: 729,040 shares
Average Volume: 1.26 million shares
Today's Range: $8.90
▼
$9.25
50-Day Range: $7.85
▼
$13.46
52-Week Range: $3.25
▼
$14.44
Dividend Yield: N/A

42. LENZ Therapeutics NASDAQ:LENZ

$24.44 +1.47 (+6.40%)

As of 03:53 PM Eastern

LENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.

Market Capitalization: $664.67 million
P/E Ratio: N/A
Consensus Rating: Buy
Consensus Price Target: $35.40 (+44.9% Upside)
Volume: 238,336 shares
Average Volume: 160,941 shares
Today's Range: $22.13
▼
$24.09
50-Day Range: $21.29
▼
$28.87
52-Week Range: $14.42
▼
$38.93
Dividend Yield: N/A

43. Sana Biotechnology NASDAQ:SANA

$2.93 +0.18 (+6.51%)

As of 03:53 PM Eastern

Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others. The company's product candidates include SC291 that is used as allogeneic cell therapies for hematologic malignancies; ARDENT for a potential treatment for non-Hodgkin's lymphoma, and chronic lymphoblastic leukemia; GLEAM, to treat multiple autoimmune disorders that involve production of autoimmune antibodies, including lupus nephritis, extrarenal lupus, antineutrophil cytoplasmic antibody -associated vasculitis, and others. It is developing SC262 to treat patients with relapsed and/or refractory B-cell malignancies; SC255 for multiple myeloma treatment; SC379, a therapy for patients with certain central nervous system disorders healthy allogeneic glial progenitor cells; SC451, a product candidate to treat diabetes, with an initial focus on type 1 diabetes mellitus; and UP421 that reduces long-term exogenous insulin dependence. The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam's proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington.

Market Capitalization: $648.60 million
P/E Ratio: -2.08
Consensus Rating: Moderate Buy
Consensus Price Target: $14.00 (+378.0% Upside)
Volume: 1.49 million shares
Average Volume: 2.96 million shares
Today's Range: $2.74
▼
$2.94
50-Day Range: $1.63
▼
$4.30
52-Week Range: $1.52
▼
$10.50
Dividend Yield: N/A

44. Relay Therapeutics NASDAQ:RLAY

$3.60 +0.13 (+3.60%)

As of 03:53 PM Eastern

Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and Migoprotafib (GDC-1971), an oral, small molecule, potent and selective inhibitor of the protein tyrosine phosphatase SHP2 that binds and stabilizes Src homology region 2 domain-containing phosphatase-2 (SHP2) as a monotherapy in patients with advanced or metastatic solid tumors. In addition, it has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of GDC-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Market Capitalization: $617.74 million
P/E Ratio: -1.40
Consensus Rating: Moderate Buy
Consensus Price Target: $19.80 (+450.8% Upside)
Volume: 1.07 million shares
Average Volume: 2.22 million shares
Today's Range: $3.38
▼
$3.66
50-Day Range: $3.19
▼
$4.92
52-Week Range: $3.02
▼
$10.72
Dividend Yield: N/A

45. Valneva NASDAQ:VALN

$7.08 +0.02 (+0.21%)

As of 03:50 PM Eastern

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine. The company also develops VLA15, a vaccine candidate, which is in Phase III clinical trial against Borrelia, the bacterium that causes Lyme disease; VLA1553, a vaccine candidate, which is in Phase III clinical trial against the chikungunya virus; VLA1554, a vaccine candidate targeting human metapneumovirus; and VLA2112, a vaccine candidate to treat patients with epstein-barr virus. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, France, rest of European countries, and internationally. Valneva SE has collaborations with Pfizer, Inc. to co-develop and commercialize its Lyme disease vaccine; and Instituto Butantan for the development, manufacturing, and marketing of single-shot chikungunya vaccine. The company was founded in 1998 and is based in Saint-Herblain, France.

Market Capitalization: $577.36 million
P/E Ratio: -54.65
Consensus Rating: Buy
Consensus Price Target: $17.00 (+140.3% Upside)
Volume: 3,080 shares
Average Volume: 25,708 shares
Today's Range: $7.11
▼
$7.29
50-Day Range: $4.31
▼
$8.33
52-Week Range: $3.62
▼
$9.50
Dividend Yield: N/A

Remove Ads

46. VectivBio NASDAQ:VECT

$16.85 0.00 (0.00%)

As of 03/7/2025

VectivBio Holding AG, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for treatments of severe rare conditions. It develops apraglutide, a long-acting synthetic peptide analog of glucagon-like peptide-2 that is in Phase III clinical trial for the treatment of patients with short bowel syndrome-intestinal failure (SBS-IF), as well as apraglutide is in Phase II clinical trial for SBS-IF in patients with colon-in-continuity anatomy. The company is also developing apraglutide, which is in Phase II clinical trial for patients with steroid-refractory gastrointestinal acute versus host disease (aGvHD). VectivBio Holding AG was incorporated in 2019 and is headquartered in Basel, Switzerland. As of June 29, 2023, VectivBio Holding AG operates as a subsidiary of Ironwood Pharmaceuticals, Inc.

Market Capitalization: $573.24 million
P/E Ratio: N/A
Consensus Rating: N/A
Consensus Price Target: N/A
Volume: N/A
Average Volume: N/A
Today's Range: $16.85
▼
$16.85
50-Day Range: $16.85
▼
$16.85
52-Week Range: $4.25
▼
$16.98
Dividend Yield: N/A

47. Immatics NASDAQ:IMTX

$4.56 +0.11 (+2.36%)

As of 03:53 PM Eastern

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes IMA203 that targets solid tumors, which is in Phase 1b clinical trial; IMA203CD8, a cell therapy product that is in Phase 1b clinical trial; IMA204 that targets tumor stroma, which is in preclinical stage; and IMA30x, an allogenic cellular therapy product candidate, which is in preclinical stage. The company also develops TCR Bispecifics products, including IMA401 and IMA402, which is in Phase 1a clinical trial. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.

Market Capitalization: $543.07 million
P/E Ratio: -6.89
Consensus Rating: Buy
Consensus Price Target: $16.67 (+265.9% Upside)
Volume: 124,535 shares
Average Volume: 587,385 shares
Today's Range: $4.43
▼
$4.62
50-Day Range: $4.18
▼
$7.42
52-Week Range: $4.06
▼
$13.77
Dividend Yield: N/A

48. Cullinan Therapeutics NASDAQ:CGEM

$9.09 +0.42 (+4.83%)

As of 03:53 PM Eastern

Cullinan Therapeutics, Inc., a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer. In addition, the company's development products comprise CLN-617, a fusion protein for the treatment of solid tumors; and CLN-978, a T cell engaging antibody for the treatment relapsed/refractory B-cell non-Hodgkin lymphoma. It has license and collaboration agreement with Adimab, LLC to discover and/or optimize antibodies; Harbour BioMed US Inc. for the development, manufacturing, and commercialization of CLN-418; and co-development agreement with Taiho Pharmaceutical Co., Ltd to develop Zipalertinib. Cullinan Therapeutics, Inc. was formerly known as Cullinan Oncology, Inc. and changed its name to Cullinan Therapeutics, Inc. in April 2024. Cullinan Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

Market Capitalization: $532 million
P/E Ratio: -3.20
Consensus Rating: Buy
Consensus Price Target: $32.86 (+261.5% Upside)
Volume: 263,126 shares
Average Volume: 465,039 shares
Today's Range: $8.63
▼
$9.19
50-Day Range: $8.00
▼
$12.68
52-Week Range: $7.90
▼
$30.19
Dividend Yield: N/A

49. Autolus Therapeutics NASDAQ:AUTL

$2.00 +0.06 (+2.84%)

As of 03:53 PM Eastern

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma. It focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. Autolus Therapeutics plc was incorporated in 2014 and is headquartered in London, the United Kingdom.

Market Capitalization: $530.86 million
P/E Ratio: -1.65
Consensus Rating: Buy
Consensus Price Target: $10.40 (+421.3% Upside)
Volume: 448,751 shares
Average Volume: 1.38 million shares
Today's Range: $1.89
▼
$2.00
50-Day Range: $1.73
▼
$2.68
52-Week Range: $1.68
▼
$6.63
Dividend Yield: N/A

50. MeiraGTx NASDAQ:MGTX

$6.37 +0.27 (+4.49%)

As of 03:53 PM Eastern

MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia. Its programs in clinical development include Phase I/II clinical stage programs in achromatopsia, X-linked retinitis pigmentosa, and RPE65-deficiency; Phase I clinical trials for radiation-induced xerostomia; and Parkinson's program that has completed a Phase II trial. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease. The company was incorporated in 2015 and is based in New York, New York.

Market Capitalization: $497.05 million
P/E Ratio: -5.26
Consensus Rating: Buy
Consensus Price Target: $23.50 (+268.7% Upside)
Volume: 190,308 shares
Average Volume: 235,196 shares
Today's Range: $6.10
▼
$6.42
50-Day Range: $5.71
▼
$7.31
52-Week Range: $3.85
▼
$7.80
Dividend Yield: N/A

Remove Ads

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Biological products, except diagnostic Stocks List

Pros of Amgen

Cons of Amgen

Pros of Gilead Sciences

Cons of Gilead Sciences

Pros of argenx

Cons of argenx

Pros of BioNTech

Cons of BioNTech

Pros of Biogen

Cons of Biogen

Pros of Moderna

Cons of Moderna

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools